Neogen (NEOG) Projected to Post Quarterly Earnings on Wednesday

Neogen (NASDAQ:NEOG) is expected to be releasing its earnings data before the market opens on Wednesday, April 9th. Analysts expect Neogen to post earnings of $0.13 per share and revenue of $225.27 million for the quarter. Neogen has set its FY 2025 guidance at EPS.

Neogen (NASDAQ:NEOG) last released its quarterly earnings results on Friday, January 10th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.12. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. The firm had revenue of $231.30 million for the quarter, compared to analysts’ expectations of $227.16 million. During the same period in the prior year, the firm earned $0.11 EPS. The business’s revenue was up .7% on a year-over-year basis. On average, analysts expect Neogen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Neogen Trading Down 3.2 %

Shares of NASDAQ:NEOG opened at $8.39 on Wednesday. The stock has a market cap of $1.82 billion, a PE ratio of -3.83 and a beta of 1.27. The company has a quick ratio of 2.46, a current ratio of 3.77 and a debt-to-equity ratio of 0.33. Neogen has a 12-month low of $8.04 and a 12-month high of $18.58. The business has a 50 day moving average of $10.02 and a 200-day moving average of $12.62.

Wall Street Analyst Weigh In

NEOG has been the topic of a number of recent research reports. Piper Sandler reaffirmed a “neutral” rating and set a $13.00 price target (down from $16.50) on shares of Neogen in a research report on Tuesday, January 21st. Guggenheim assumed coverage on shares of Neogen in a research report on Thursday, December 19th. They issued a “buy” rating and a $15.00 price target for the company.

Insiders Place Their Bets

In other Neogen news, CFO David H. Naemura purchased 14,800 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were bought at an average price of $11.11 per share, for a total transaction of $164,428.00. Following the purchase, the chief financial officer now owns 61,434 shares in the company, valued at approximately $682,531.74. This trade represents a 31.74 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John Edward Adent acquired 23,035 shares of Neogen stock in a transaction that occurred on Thursday, January 16th. The stock was acquired at an average cost of $11.03 per share, for a total transaction of $254,076.05. Following the completion of the purchase, the chief executive officer now directly owns 269,164 shares of the company’s stock, valued at $2,968,878.92. This represents a 9.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.13% of the company’s stock.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.